* CRL did not cite any concerns with clinical safety and
efficacy data for ri-002 submitted by adma in bla
The post BRIEF-Adma Biologics receives CRL from FDA for pending biologics license application appeared first on NASDAQ.
BRIEF-Adma Biologics receives CRL from FDA for pending biologics license application
